Among these inhibitors, gabapentin is the most commonly used BCAT1 inhibitor, which has demonstrated in vitro or in vivo antitumor efficacies in glioblastoma, hepatocellular carcinoma, and CML.13,30,38,39 Additional compounds, such as BCATc inhibitor 2, ERG240, tubercidin, lycorine HCl, and BAY-069 also shown promising BCAT1-targeting activities.40–42 While BCATc inhibitor 2 and ERG240 have demonstrated neuroprotective effects or alleviated autoimmune diseases in murine models, their antitumor efficacy remains unexplored. The gene discussed is BCAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.